Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0194-0499 in Renal Impairment
NCT05727644Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of nn9500 in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum concentration-time curve from time zero to infinity. Started Feb 2023; status: completed.
02
Drugs
nn9500
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05727644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727644.